0001654954-23-002026.txt : 20230224 0001654954-23-002026.hdr.sgml : 20230224 20230224063736 ACCESSION NUMBER: 0001654954-23-002026 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230224 FILED AS OF DATE: 20230224 DATE AS OF CHANGE: 20230224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 23662279 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a9851q.htm DIRECTOR/PDMR SHAREHOLDING a9851q

 
FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of February 2023
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X                    Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __                       No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
 
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
Director/PDMR Shareholding
 
 
24 February 2023 11:00 GMT
 
Transaction by Person Discharging Managerial Responsibilities
 
AstraZeneca PLC (the Company) announces that, on 22 February 2023, it was notified by Aradhana Sarin, Executive Director and Chief Financial Officer, that, on 17 February 2023, Dr Sarin ceased to be beneficially interested in 200 American Depositary Shares (ADSs) of the Company, following the gift of those shares to charity for nil consideration. Each ADS represents one half of an ordinary share of $0.25 each in the Company.
 
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
 
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
a)
 
Name
Aradhana Sarin
2
 
Reason for the notification
 
a)
 
Position/status
 
Chief Financial Officer
b)
 
Initial notification/Amendment
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
AstraZeneca PLC
b)
 
LEI
PY6ZZQWO2IZFZC3IOL08
4i
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
 
Description of the financial instrument, type of instrument
 
 
 
Identification code
AstraZeneca PLC American Depositary Shares
 
 
 
CUSIP: 046353108
 
b)
 
Nature of the transaction
 
 
Gift of shares to charity for nil consideration
c)
 
Price(s) and volume(s)
Price(s)
Volume(s)
 
0
200
 
d)
 
Aggregated information
 
- Aggregated volume
 
- Price
 
Not applicable - single transaction
 
 
 
 
e)
 
Date of the transaction
 
17 February 2023
f)
 
Place of the transaction
 
Outside a trading venue
 
 
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 24 February 2023
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary